Project Grant R01HL177653
Award Date
12/15/24
Completion Date
11/30/28
Dollars Obligated
$615K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
This $165,672 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at The Leland Stanford Junior University to investigate the role of cardiac troponin I (cTnI) in regulating mitochondrial function and its implications for inherited cardiomyopathies.
The key objectives are to: 1) determine the effects of cTnI phosphorylation and truncation on mitochondrial function, and 2) evaluate the...
This $756,039 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate how non-coding genetic variants affect the severity of cardiomyopathies caused by haploinsufficiency. The grantee, the Regents of the University of Michigan, will utilize human induced pluripotent stem cell-derived cardiomyocytes and mouse models to quantify the gene expression impacts of single...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $624,142 to the University of Colorado-Denver to conduct an integrated genomic and transcriptomic investigation of human heart failure mechanisms. The project aims to leverage whole-genome and whole-transcriptome data from a unique dataset of ~750 paired DNA/RNA sequenced human heart samples to: 1) validate which heart failure GWAS...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on the mechanisms of diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The key objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the regulation of relaxation, and determine the mechanistic effects...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,507,438 to the University of Washington to perform a deep mutational scan of the MYH7 gene in genome-edited human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). The key objectives are to: 1) Generate a single nucleotide variant library of nearly all possible MYH7 variants in hiPSC-CMs using a novel...
This federal Project Grant award of $620,371 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to determine the voltage-sensing domain (VSD) dynamics of recombinant cyclic nucleotide-binding domain (CNBD) channels, including hyperpolarization-activated cyclic nucleotide-gated (HCN) and depolarization-activated KCNH channels. The research aims to improve the understanding of the...
This Federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting research to leverage large-scale biobanks to discover and define rare genetic variant effects on hypertrophic cardiomyopathy (HCM). The $767,579 award to Vanderbilt University Medical Center (VUMC) aims to address key knowledge gaps by: 1) defining the contribution and phenotypic manifestations of established HCM disease...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project aims to leverage high-throughput functional genomic approaches, including cell painting and Perturb-seq, to systematically assess the impact of HF-associated genetic risk loci on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $680,831 to the University of Connecticut Health Center (UCHC) to conduct research on calcium signaling mechanisms in cardiac fibrogenesis.
The key products and services to be delivered under this 4-year grant include:
Investigating whether the channel function or kinase function of the TRPM7 protein in cardiac fibroblasts contributes...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $782,672 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Brigham & Women's Hospital. The grant funding will support research to identify previously unrecognized genetic causes of congenital heart disease (CHD). The project aims to assess the contributions of non-coding and rare coding variants to unexplained CHD cases, using a combination of cell-based functional assays, single-nucleus RNA...